SEC Form 4 · accession 0001209191-17-035151
G1 Therapeutics, Inc. · GTHX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
MedImmune Ventures, Inc.
10% Owner
Period of report
May 22, 2017
Accepted (ET)
May 24, 2017 · 7:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001560241
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 22, 2017 | C | 3,409,536 | — | A | 3,409,536 | D | |
| Common StockF2 | May 22, 2017 | P | 75,000 | $15.00 | A | 3,484,536 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Preferred StockF1,F3 | — | May 22, 2017 | C | 7,142,857 | D | — | — | Common Stock | 2,380,952 | 0 | D |
| Series B Preferred StockF1,F3 | — | May 22, 2017 | C | 2,412,628 | D | — | — | Common Stock | 804,208 | 0 | D |
| Series C Preferred StockF1,F3 | — | May 22, 2017 | C | 673,128 | D | — | — | Common Stock | 224,376 | 0 | D |
Explanation of responses
- F1The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's Fifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted to Common Stock on a 1-for-3 basis.
- F2Reflects shares the reporting person purchased in the initial public offering at the initial public offering price of $15.00 per share.
- F3The Series A Preferred Stock, Series B Preferred Stock and the Series C Preferred Stock automatically converted into shares of Common Stock upon consummation of the Issuer's initial public offering and had no expiration date.